We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 42

High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • January 9 2013

In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge

EC introduces major changes to medical device regulation

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • December 17 2012

The European Commission has issued two proposals that, if approved, will fundamentally amend EU law on medical devices and in vitro diagnostics

What did you say? $31 million awarded for infringement of hearing aid patent

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed

Increased European patent protection following a landmark ruling on supplementary protection certificates

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • August 30 2012

The Court of Justice of the European Union (CJEU) rendered judgment relating to a preliminary reference from the English Court of Appeal, holding that the existence of an earlier marketing authorization (MA) of a pharmaceutical product does not preclude the grant of a Supplementary Protection Certificate (SPC) for a different application of the same product

Advocate General opinion on the interpretation of “first marketing authorisation” for Supplementary Protection Certificates

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • June 7 2012

Advocate General Trstenjak (the AG) has rendered an opinion in a preliminary reference relating to Neurim Pharmaceuticals Ltd 1991 C-13011 that it should be possible to grant a Supplementary Protection Certificate (SPC) for a second medicinal product that comprises the same active ingredient as a medicinal product covered by a prior marketing authorisation (MA), if the scope of the basic patent protecting the second medicinal product does not extend to the earlier medicinal product

Navigating the evolving regulation and commercialization of stem cell research

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage

UK Supreme Court steps into line with Europe, but rejects U.S. approach

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom, USA
  • -
  • November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily

SPCs: is a simplistic system becoming too complicated?

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 22 2010

Obtaining and enforcing Supplementary Protection Certificates (SPCs) for medicinal products in the European Union is a fertile ground for challenge and the law is still unclear in a number of key areas

Controlling and processing data in EU clinical trials

  • McDermott Will & Emery
  • -
  • European Union
  • -
  • November 22 2010

The legal regime for the conduct of clinical trials of medicinal products for human use in the European Union is set out in Directive 200120EC (the Clinical Trials Directive

Divergences in industrial applicability between the United Kingdom and the European Patent Office

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom
  • -
  • April 30 2010

Rejecting an appeal by Human Genome Sciences Inc (HGS), the Court of Appeal of England and Wales in Eli Lilly and Co v Human Genome Sciences Inc 2010 EWCA Civ 33 upheld the finding that HGS' patent (as amended) was invalid for lack of industrial applicability

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy